Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald

Ozgul GoK, Christina L. Nemeth, Bela Turk, Siva Pramodh Kambhampati, Fan Zhang, Anjali Sharma, Sujatha Kannan, Ali Fatemi, Kannan Rangaramanujam

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Statement of Purpose: Delivery of therapeutics acros s the blood-brain barrier (BBB) to selectively treat injured brain areas is a major challenge (Kannan, R. M. J Intern Med 2014; 276: 579– 617) and has been a limiting factor for the treat ment of several neurodevelopmental disorders. X-linked adrenoleu kodystrophy (ALD) is a rare genetic dis ease which results in the rapid demyelination of the brain, most severely occurring during childhood. With their great potential as drug/gene delivery nanovehicles, dendrimers provide lots of advantageous features like monodispersity, mu ltivalency, enhanced water solubility and functionalization by imaging agents and targeting groups. We have shown that polyamidoamine (PAMAM) dendrimers can pass through the impaired BBB without any need for additional targeting ligands and localize in the inju red site based on the extent of injury (Zhang, F. J. Neuroin flammation 2016;3-65). In a neonatal rabbit model of cerebral palsy (CP), Cy5-labeled, generation-4 PAMAM dendrimer (D-Cy5) was shown to accumulate almost 20 times more in the brains of rabbit kits with CP, co mpared to healthy controls (Figure 1) (Lesniak, W. G. Mol. Pharmaceutics 2013;10:4560-4571). In light of these findings, a novel PAMAM-based drug delivery system was designed for the delivery of ABCD2 gene regulating drug, 4-phenyl butyrate (PBA), as a brain targeting nano-vehicle with a sustained and slow drug release profile.

Original languageEnglish (US)
Title of host publicationSociety for Biomaterials Annual Meeting and Exposition 2019
Subtitle of host publicationThe Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting
PublisherSociety for Biomaterials
Number of pages1
ISBN (Electronic)9781510883901
StatePublished - Jan 1 2019
Event42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States
Duration: Apr 3 2019Apr 6 2019

Publication series

NameTransactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
Volume40
ISSN (Print)1526-7547

Conference

Conference42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
CountryUnited States
CitySeattle
Period4/3/194/6/19

Fingerprint

Nanomedicine
Medical nanotechnology
Dendrimers
Brain
Cerebral Palsy
Blood-Brain Barrier
Pharmaceutical Preparations
Genes
Rabbits
Butyrates
Demyelinating Diseases
Therapeutics
Drug Delivery Systems
Solubility
Ligands
Imaging techniques
Water
Wounds and Injuries
Poly(amidoamine)
cyanine dye 5

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Biotechnology
  • Biomaterials
  • Materials Chemistry

Cite this

GoK, O., Nemeth, C. L., Turk, B., Kambhampati, S. P., Zhang, F., Sharma, A., ... Rangaramanujam, K. (2019). Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40). Society for Biomaterials.

Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald. / GoK, Ozgul; Nemeth, Christina L.; Turk, Bela; Kambhampati, Siva Pramodh; Zhang, Fan; Sharma, Anjali; Kannan, Sujatha; Fatemi, Ali; Rangaramanujam, Kannan.

Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

GoK, O, Nemeth, CL, Turk, B, Kambhampati, SP, Zhang, F, Sharma, A, Kannan, S, Fatemi, A & Rangaramanujam, K 2019, Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald. in Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium, vol. 40, Society for Biomaterials, 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence, Seattle, United States, 4/3/19.
GoK O, Nemeth CL, Turk B, Kambhampati SP, Zhang F, Sharma A et al. Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials. 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).
GoK, Ozgul ; Nemeth, Christina L. ; Turk, Bela ; Kambhampati, Siva Pramodh ; Zhang, Fan ; Sharma, Anjali ; Kannan, Sujatha ; Fatemi, Ali ; Rangaramanujam, Kannan. / Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald. Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).
@inproceedings{6d5b7f18c9f9406f85d920d8fd33e109,
title = "Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald",
abstract = "Statement of Purpose: Delivery of therapeutics acros s the blood-brain barrier (BBB) to selectively treat injured brain areas is a major challenge (Kannan, R. M. J Intern Med 2014; 276: 579– 617) and has been a limiting factor for the treat ment of several neurodevelopmental disorders. X-linked adrenoleu kodystrophy (ALD) is a rare genetic dis ease which results in the rapid demyelination of the brain, most severely occurring during childhood. With their great potential as drug/gene delivery nanovehicles, dendrimers provide lots of advantageous features like monodispersity, mu ltivalency, enhanced water solubility and functionalization by imaging agents and targeting groups. We have shown that polyamidoamine (PAMAM) dendrimers can pass through the impaired BBB without any need for additional targeting ligands and localize in the inju red site based on the extent of injury (Zhang, F. J. Neuroin flammation 2016;3-65). In a neonatal rabbit model of cerebral palsy (CP), Cy5-labeled, generation-4 PAMAM dendrimer (D-Cy5) was shown to accumulate almost 20 times more in the brains of rabbit kits with CP, co mpared to healthy controls (Figure 1) (Lesniak, W. G. Mol. Pharmaceutics 2013;10:4560-4571). In light of these findings, a novel PAMAM-based drug delivery system was designed for the delivery of ABCD2 gene regulating drug, 4-phenyl butyrate (PBA), as a brain targeting nano-vehicle with a sustained and slow drug release profile.",
author = "Ozgul GoK and Nemeth, {Christina L.} and Bela Turk and Kambhampati, {Siva Pramodh} and Fan Zhang and Anjali Sharma and Sujatha Kannan and Ali Fatemi and Kannan Rangaramanujam",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
series = "Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium",
publisher = "Society for Biomaterials",
booktitle = "Society for Biomaterials Annual Meeting and Exposition 2019",

}

TY - GEN

T1 - Design of a dendrimeric nanomedicine pl atform for the treatment of a neuro-degenerati ve disease, x-ald

AU - GoK, Ozgul

AU - Nemeth, Christina L.

AU - Turk, Bela

AU - Kambhampati, Siva Pramodh

AU - Zhang, Fan

AU - Sharma, Anjali

AU - Kannan, Sujatha

AU - Fatemi, Ali

AU - Rangaramanujam, Kannan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Statement of Purpose: Delivery of therapeutics acros s the blood-brain barrier (BBB) to selectively treat injured brain areas is a major challenge (Kannan, R. M. J Intern Med 2014; 276: 579– 617) and has been a limiting factor for the treat ment of several neurodevelopmental disorders. X-linked adrenoleu kodystrophy (ALD) is a rare genetic dis ease which results in the rapid demyelination of the brain, most severely occurring during childhood. With their great potential as drug/gene delivery nanovehicles, dendrimers provide lots of advantageous features like monodispersity, mu ltivalency, enhanced water solubility and functionalization by imaging agents and targeting groups. We have shown that polyamidoamine (PAMAM) dendrimers can pass through the impaired BBB without any need for additional targeting ligands and localize in the inju red site based on the extent of injury (Zhang, F. J. Neuroin flammation 2016;3-65). In a neonatal rabbit model of cerebral palsy (CP), Cy5-labeled, generation-4 PAMAM dendrimer (D-Cy5) was shown to accumulate almost 20 times more in the brains of rabbit kits with CP, co mpared to healthy controls (Figure 1) (Lesniak, W. G. Mol. Pharmaceutics 2013;10:4560-4571). In light of these findings, a novel PAMAM-based drug delivery system was designed for the delivery of ABCD2 gene regulating drug, 4-phenyl butyrate (PBA), as a brain targeting nano-vehicle with a sustained and slow drug release profile.

AB - Statement of Purpose: Delivery of therapeutics acros s the blood-brain barrier (BBB) to selectively treat injured brain areas is a major challenge (Kannan, R. M. J Intern Med 2014; 276: 579– 617) and has been a limiting factor for the treat ment of several neurodevelopmental disorders. X-linked adrenoleu kodystrophy (ALD) is a rare genetic dis ease which results in the rapid demyelination of the brain, most severely occurring during childhood. With their great potential as drug/gene delivery nanovehicles, dendrimers provide lots of advantageous features like monodispersity, mu ltivalency, enhanced water solubility and functionalization by imaging agents and targeting groups. We have shown that polyamidoamine (PAMAM) dendrimers can pass through the impaired BBB without any need for additional targeting ligands and localize in the inju red site based on the extent of injury (Zhang, F. J. Neuroin flammation 2016;3-65). In a neonatal rabbit model of cerebral palsy (CP), Cy5-labeled, generation-4 PAMAM dendrimer (D-Cy5) was shown to accumulate almost 20 times more in the brains of rabbit kits with CP, co mpared to healthy controls (Figure 1) (Lesniak, W. G. Mol. Pharmaceutics 2013;10:4560-4571). In light of these findings, a novel PAMAM-based drug delivery system was designed for the delivery of ABCD2 gene regulating drug, 4-phenyl butyrate (PBA), as a brain targeting nano-vehicle with a sustained and slow drug release profile.

UR - http://www.scopus.com/inward/record.url?scp=85065400567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065400567&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:85065400567

T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium

BT - Society for Biomaterials Annual Meeting and Exposition 2019

PB - Society for Biomaterials

ER -